In a significant move to address serious mental health issues, the FDA is fast-tracking the review of several psychedelic drugs, including psilocybin and ibogaine, in response to a recent executive order from President Trump. This directive aims to enhance research capabilities and expedite approval processes for treatments targeting conditions like PTSD, particularly for veterans. Analysts note that while the executive order has symbolic value, it also represents a shift in drug policy within the GOP, reflecting a growing acceptance of psychedelic therapies. The FDA has already issued priority review vouchers for three drug trials, signaling a commitment to advancing mental health treatments at an accelerated pace. Meanwhile, stakeholders express excitement about the potential benefits but also raise concerns regarding therapy costs and resource availability.